Please use this identifier to cite or link to this item:
|Title:||Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis|
|Authors:||Brown, Victoria A.|
Patel, Ketan R.
Crowell, James A.
Booth, Tristan D.
Schinas, Anna Maria
Steward, William P.
Gescher, Andreas J.
Brenner, Dean E.
|Publisher:||American Association for Cancer Research|
|Citation:||Cancer Research, 2010, 70 (22), pp. 9003-9011.|
|Abstract:||Resveratrol, a naturally occurring polyphenol, has cancer chemopreventive properties in preclinical models. It has been shown to downregulate the levels of insulin-like growth factor-1 (IGF-I) in rodents. The purpose of the study was to assess its safety, pharmacokinetics, and effects on circulating levels of IGF-I and IGF-binding protein-3 (IGFBP-3) after repeated dosing. Forty healthy volunteers ingested resveratrol at 0.5, 1.0, 2.5, or 5.0 g daily for 29 days. Levels of resveratrol and its metabolites were measured by high performance liquid chromatography-UV in plasma obtained before and up to 24 hours after a dose between days 21 and 28. IGF-I and IGFBP-3 were measured by ELISA in plasma taken predosing and on day 29. Resveratrol was safe, but the 2.5 and 5 g doses caused mild to moderate gastrointestinal symptoms. Resveratrol-3-O-sulfate, resveratrol-4′-O-glucuronide, and resveratrol-3-O-glucuronide were major plasma metabolites. Maximal plasma levels and areas under the concentration versus time curve for the metabolites dramatically exceeded those for resveratrol, in the case of areas under the concentration versus time curve, by up to 20.3-fold. Compared with predosing values, the ingestion of resveratrol caused a decrease in circulating IGF-I and IGFBP-3 (P < 0.04 for both), respectively, in all volunteers. The decrease was most marked at the 2.5 g dose level. The results suggest that repeated administration of high doses of resveratrol generates micromolar concentrations of parent and much higher levels of glucuronide and sulfate conjugates in the plasma. The observed decrease in circulating IGF-I and IGFBP-3 might contribute to cancer chemopreventive activity.|
|Rights:||Copyright © 2010 American Association for Cancer Research. Deposited with reference to the publisher's archiving policy available on the SHERPA/RoMEO website.|
This paper was published as Cancer Research, 2010, 70 (22), pp. 9003-9011. It is available from http://cancerres.aacrjournals.org/content/70/22/9003 or from http://ukpmc.ac.uk/abstract/MED/20935227. Doi: 10.1158/0008-5472.CAN-10-2364
|Appears in Collections:||Published Articles, Dept. of Cancer Studies and Molecular Medicine|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.